Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
A New Ozempic? Researchers Develop New Weight Loss Drug That Doesn't Cause Nausea
The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often come with side effects such as nausea.
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
I’m a weight-loss doctor — the unusual complication I’m seeing from Ozempic-like drugs
A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like Ozempic.
Ozempic, Wegovy, and Mounjaro: Your Go-To Guide for Weight Loss with Meds
Everything you need to know about using Ozempic, Wegovy, and Mounjaro to shed those extra pounds. We dive into their perks, potential pitfalls, and why you should always have a doc on board.
1d
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
STAT
21h
In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
MedCity News
1d
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...
9d
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
8d
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
2d
on MSN
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Healio
23h
The year in obesity: New data on semaglutide and tirzepatide, sarcopenic obesity and more
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
The Hill
12d
RFK Jr. vs. Oz sets up clash on weight loss drug coverage
Currently, only 13 states cover GLP-1
drugs
for
obesity
under Medicaid. But a
new
proposal announced by the Biden ...
Opinion
Medpage Today on MSN
13d
Opinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.
This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
4d
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
FiercePharma
2d
Fueled by new launches, US drug prices poised to continue trending upward: Cowen report
Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback